ClinicalTrials.gg
RecruitingNCT07200206Updated Nov 12, 2026

A Post-marketing Surveillance Study of Beyfortus (Nirsevimab) in Republic of Korea

An observational study in Respiratory Syncytial Virus, sponsored by Sanofi. Recruiting at 1 site in South Korea. Open to participants aged 0 Days to 24 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Sanofi · Observational

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Nov 12, 2026Eligibility revised1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
3,000
Ages
0 Days to 24 Months
Sex
All
01

Study summary

This study is conducted as part of the local risk management plan to collect and understand the following information about the surveillance drug under the real-world clinical practice settings.

To evaluate the safety of Beyfortus in Korean children who received Beyfortus under the real-world clinical practice settings per the approved indication. The investigator will decide whether to enroll participants if they determine that administering Beyfortus according to current practice can provide clinical benefits in terms of safety and efficacy Participants will be followed-up for 180 days after Beyfortus administration.

02

Conditions studied

  • Respiratory Syncytial Virus
03

In context

Lead sponsor

Sanofi is the lead sponsor of 1,560 studies on the registry; 90 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 12, 2026. See what changed

Ages eligible
0 Days to 24 Months
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Children up to 24 months of age who are scheduled to receive Beyfortus according to the approved indications will be selected as participants under the real-world clinical practice settings during the surveillance period after the contract date at the institution. The participants must meet all study inclusion criteria and must not meet any of the study exclusion criteria.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children up to 24 months of age who received Beyfortus according to the approved indications.
  • signed by the parents / legally accepted representatives (LARs) of the participant.

Exclusion criteria

Exclusion Criteria:

  • Participation at the time of study enrollment (or in the 4 weeks preceding the enrollment) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device or a medical procedure.
  • Any according to the approved local product label of Beyfortus.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
3,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Cohort 1

    Children up to 24 months of age who are scheduled to receive Beyfortus according to the approved indications will be selected as participants under the real-world clinical practice settings during the surveillance period.

    Biological: Nirsevimab

Interventions

  • BiologicalNirsevimab

    Route of Administration: Intramuscular Pharmaceutical Form: Solution for injection

    Also known as: Beyfortus™

06

What researchers measure

Primary outcomes

  1. Occurence of Adverse Events (AEs)

    Number of participants (and occurrences) experiencing AEs will be assessed.

    Time frame: Up to 180 days post dose

  2. Occurence of Serious Adverse Events (SAEs)

    Number of participants (and occurrences) experiencing SAEs will be assessed.

    Time frame: Up to 180 days post dose

  3. Occurrence of AE of special interest (AESI)

    Number of participants (and occurrences) experiencing AESI will be assessed. The definition of AESI is as follow: 1. Hypersensitivity, including anaphylaxis 2. Immune complex disease 3. Thrombocytopenia

    Time frame: Up to 180 days post dose

  4. Occurence of Adverse Drug Reaction (ADRs) as Specified in Approved Local Label

    Number of participants (and occurrences) experiencing ADRs will be assessed.

    Time frame: Up to 180 days post dose

  5. Occurrence of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Infection (LRTI)

    Number of participants (and occurrences) experiencing RSV LRTI will be assessed.

    Time frame: Up to 180 days post dose

07

Study locations

1 of 1 sites recruiting
  • Investigational Site Number : 4100007
    Hwaseong-si, Gyeonggi-do, 18478, South Korea
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Sep 2029, 47 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2025
First posted
Oct 1, 2025
StartActual
Oct 2, 2025
Primary completionEst.
Sep 26, 2029
CompletionEst.
Sep 26, 2029
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Investigational Site Number : 4100007 · Hwaseong-si, Gyeonggi-do, South Korea
Show 1 removed
  • Nam Seung Woo Pediatric: 4100007 · Hwaseong-si, Gyeonggi-do, South Korea
Nov 12, 2026
Eligibility
1 exclusion criterion added
What changed in the criteria
Exclusion criteria
  • AddedThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    1 site added, 1 site removed
    Show site
    • Investigational Site Number : 4100007 · Hwaseong-si, Gyeonggi-do, South Korea
    Show 1 removed
    • Nam Seung Woo Pediatric: 4100007 · Hwaseong-si, Gyeonggi-do, South Korea
    Eligibility 1 exclusion criterion added
    What changed in the criteria
    Exclusion criteria
    • AddedThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07200206
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Oct 1, 2025
Start date
Oct 2, 2025
Primary completion
Sep 26, 2029 (estimated)
Completion
Sep 26, 2029 (estimated)
Last update
Nov 12, 2026

Study contacts

Trial Transparency email recommended (Toll free for US & Canada)
Contact
Contact-US@sanofi.com
800-633-1610 ext. option 6

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion